SCHEMBL902441

SCHEMBL902441

CCOC(=O)Cc1nc2ccnn2c(O)c1Cc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.42
KDM4E B2RXH2 6/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
HSD17B10 Q99714 3/20 0.39
ALDH1A1 P00352 4/20 0.39
RAB9A P51151 1/20 0.39
SLC2A2 P11168 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 3/20 0.37
HPGD P15428 2/20 0.37
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15274696 0.86 ALDH1A1 (0.36) KDM4EALDH1A1RAB9AHTTHPGD
SCHEMBL15261556 0.83 PRKAB2 (0.37) KDM4EMEN1KMT2ATDP1ALDH1A1
SCHEMBL902390 0.80 PDE10A (0.35) MAPTKDM4EL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL902589 0.80 PDE10A (0.38) KDM4EALDH1A1HTTHPGD
SCHEMBL902629 0.79 APLNR (0.35) KDM4EHSD17B10ALDH1A1HTTHPGD
SCHEMBL902316 0.78 ENPP2 (0.47) MAPTKDM4EKMT2AL3MBTL1HSD17B10
SCHEMBL2040044 0.77 MAPT (0.47) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL902369 0.76 PDE4B (0.40) MAPTKMT2AALDH1A1
SCHEMBL902279 0.76 MAPK1 (0.37) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL902910 0.74 NPC1 (0.40) KDM4EKMT2AL3MBTL1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 MAPT 4334/4885KDM4E 4265/4885MEN1 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.